Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Normandt1965on Jun 08, 2022 3:08pm
159 Views
Post# 34741284

RE:RE:RE:RE:RE:RE:RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliff

RE:RE:RE:RE:RE:RE:RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliffMy quote was coming from wikipedia. I verified differents sites and no ones gives the same numbers of patents for Oncy. Itt's not because wiki gives a number and another site gives another one lower that means we lost x number of patents recently. I really think it gives nothing to mention it right now, since we just don't know which ones are expired (maybe Noteable knows the details) ....it's the same idea for all the small ang big pharma companies even Pfizer or Roche, or whatever which company, ...each years they have patents expired and there is no corrolation between that and the future success.
<< Previous
Bullboard Posts
Next >>